期刊文献+

胸腺瘤上皮生长因子受体的表达及其临床意义 被引量:4

Expression of EGFR in thymoma and its clininical significance
在线阅读 下载PDF
导出
摘要 目的 研究上皮生长因子受体 (EGFR)在胸腺瘤中的表达水平及其与临床病理关系。方法 应用SABC免疫细胞化学方法检测EGFR在 6 2例胸腺瘤组织和 8例正常胸腺组织中的表达程度。结果 EGFR在胸腺瘤中的表达率及染色强度均显著高于正常胸腺组织 (P <0 .0 1) ;EGFR随着胸腺瘤Masaoka分期进展而染色强度呈增高趋势 ;在合并严重的重症肌无力(MG)的胸腺瘤中EGFR的染色程度明显增强。结论 EGFR与胸腺瘤及重症肌无力的发生、发展有一定的内在联系 ,EGFR高表达者 ,肿瘤的侵袭性强 ,出现严重的MG的几率高 ,预后不理想 ,需加强术后治疗和随访。 Objective To investigate the expression level of EGFR in thymoma and its pathological and clinical correlation. Methods The expression of EGFR was studied in 62 cases of thymoma and 8 cases of normal thymus tissue through immunohistochemistry. Results The expression rate and intensity were significantly higher in thymoma than those in normal tissue(P< 0.01); The expression intensity in thymoma showed a tendency to increase as the Masaoka stage advances;The EGFR expression intensity was significantly stronger in thymoma with severe MG. Conclusion The expression of EGFR can be linked to the generation and progression of thymoma and MG that is the higher the expression level of EGFR the more invasive the tumor is and the more likely severe MG develops. As the prognosis is poor in these cases it is important to strengthen postoperative treatment and follow up.
出处 《肿瘤》 CAS CSCD 北大核心 2003年第6期502-504,共3页 Tumor
关键词 胸腺瘤 上皮生长因子受体 表达 重症肌无力 免疫细胞化学染色 Epidermal growth factor receptor Thymoma Myasthenia Gravis
  • 相关文献

参考文献10

  • 1[1]Fromowitz FB, Viola MV, Chao S, et al. Ras p21 expression in the progression of breast cancer[J]. Hum Pathol, 1987,18:1268
  • 2[2]Kirchner T,Schalke B,Marx A,et al. Evaluation of prognostic features in thymic epithelial tumors[J]. Thymus, 1989,14:195
  • 3[3]Hayashi Y,Ishii N,Obayashi C,et al. Thymoma:tumor type related to expression of epidermal growth factor, EGF-receptor,p53,v-erB and ras p21[J]. Virchows Arch,1995,426(1) :43
  • 4[4]Gilhus NE,Jones M, Turley H, et al. Oncogene protein and proliferation antigens in thymomas increased expression of epidermal growth factor receptor and Ki67 antigen[J]. J Clin Pathol, 1995,48(5) :447
  • 5[5]Chen WS, Lazar CS, Poenie M, et al. Requirements for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor[J]. Nature, 1987,328: 820
  • 6[6]Korkolopoulou P, Oates J, Kittas C, et al. p53, c-myc p-62and proliferating cell nuclear antigen(PCNA) expression in non Hodgkin's lymphomas[J]. J Clin pathol, 1994,47: 9
  • 7[7]Levitzki A, Tyrosine kinase inhibition: an approach to drug development[J]. Science. 1995,267: 1782
  • 8[8]Verbeek BS,Adriaansen-Slot SS, Vroom TM, et al. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts[J].FEBS. 1998,425:145
  • 9[9]Sewell JM, Macleod KG, Ritchie A, et al. Targeting the EGF receptor in ovarian cancer the tyrosine kinase inhibitor ZD1839[J]. Br J Cancer. 2002,86:456
  • 10[10]Kaufmann AM,Lichtner RB, Schirrmacher V, et al. Induction of apoptosis by EGF receptor in rat mammary adenocarcinoma cells coincides with enhanced spontaneous tumor metastasis[J]. J Oncology, 1996,13 (11): 2349

同被引文献71

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部